Description: Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Home Page: www.portagebiotech.com
PRTG Technical Analysis
Craigmuir Chambers
Tortola,
VG1110
British Virgin Islands
Phone:
416-929-1806
Officers
| Name | Title |
|---|---|
| Dr. Ian B. Walters M.B.A., M.D. | CEO & Chairman of Board |
| Mr. Allan J. Lee Shaw CPA | Chief Financial Officer |
| Mr. Steven Innaimo | VP of Project Management & Operations |
| Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer |
| Mr. Brian Wiley | Chief Bus. Officer |
| Mr. Joseph Ciavarella | Chief Accounting Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5308 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-25 |
| Fiscal Year End: | March |
| Full Time Employees: | 6 |